Cassinello, JArranz, J APiulats, J MSanchez, APerez-Valderrama, BMellado, BCliment, M AOlmos, DCarles, JLazaro, M2023-01-252023-01-252017-11-13Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57-68http://hdl.handle.net/10668/11795Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AbirateroneAndrogen deprivation treatmentCabazitaxelCastration-resistant prostate cancerDocetaxelEnzalutamideHormone-sensitive advanced prostate cancerRadium 223Antineoplastic AgentsHumansMaleProstatic Neoplasmsresearch article29134562open accessDocetaxelNeoplasias de la PróstataCastraciónPróstata10.1007/s12094-017-1783-21699-3055PMC5785604https://link.springer.com/content/pdf/10.1007/s12094-017-1783-2.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785604/pdf